Edwards Lifesciences' RESILIA Tissue Shows 10-Year Durability in COMMENCE Trial
Event summary
- 10-year COMMENCE trial data show 97.9% freedom from structural valve deterioration in Edwards' RESILIA tissue valves.
- Trial enrolled younger patients, historically at higher risk of valve deterioration.
- RESILIA tissue designed to resist calcification, a leading cause of valve failure.
- Over 500,000 patients treated worldwide with Edwards' RESILIA-based valves.
The big picture
As patients live longer and expect to remain active, the demand for durable structural heart therapies is increasing. Edwards' 10-year data on RESILIA tissue positions the company to capitalize on this trend, particularly as earlier intervention in valve disease becomes more common. The results reinforce Edwards' role as a leader in structural heart innovation, with implications for both surgical and transcatheter valve markets.
What we're watching
- Market Expansion
- How Edwards will leverage these results to expand use in younger patients.
- Competitive Positioning
- Whether this data will solidify Edwards' leadership in durable valve technologies.
- Regulatory Dynamics
- The pace at which FDA-approved studies will incorporate RESILIA tissue data.